Antibiotic Resistance: Market Developments, Growth Areas and Opportunities 2014
DUBLIN, April 8, 2014 /PRNewswire/ –
Research and Markets (http://www.researchandmarkets.com/research/mt7l8d/antibiotic
) has announced the addition of the “Antibiotic Resistance: Market Developments, Growth
Areas and Opportunities 2014″
[http://www.researchandmarkets.com/research/mt7l8d/antibiotic ] report to their offering.
Threats posed by the global increase in antibiotic resistant bacterial strains
continue to cause alarm, and some observers suggest that this problem is threatening to
take societies back to a pre-antibiotic era. However, the last five years have seen
important changes in practices, innovation and attitudes, in response to this growing
threat. Biopharm Reports has recently carried out a global market study of antibiotic
resistance, to identify the changing developments and management strategies that are
taking place, and the opportunities these offer to developers in this field.
This report has carried out a global market study of antibiotics resistance, to
identifying the changes that are taking place in the antibiotic resistance market’ and the
opportunities these present to developers in this field. This global study involved the
participation of 652 clinicians, scientists, researchers and Government officials in 80
countries and provides a comprehensive overview of current and evolving practices,
developments and strategies and their importance in the combating and management of
This report provides a wealth of information for companies and Government departments
working in this field, and through a detailed analysis of the study’s findings, identifies
commercial opportunities and provides insights, which will help to guide decision-making
in this challenging field.
While the emergence of MRSA has embodied concerns over the rise of antibiotic
resistance, other trends are becoming increasingly problematic. An example is the
emergence of carbapenem resistance in K. pneumonia, due to a lack of alternative treatment
options. Reports from the US suggest that 50-60% of all hospital-acquired infections are
caused by antibiotic resistant bacteria, illustrating the human and financial impact of
antibiotic resistance. In 2009, the World Health Organisation reported that in Europe
25,000 people die every year from drug-resistant infections. In the same year there were
440,000 new cases of MDR tuberculosis, in 69 countries.
Although the use of antibiotics has soared in recent decades, the approval of new
antibiotics in the US fell by 60% from 30 during the decade 1983 to 1992, to just 12 over
the period 1998 to 2009. Although recent years have seen a significant growth in the
numbers and novelty of new pipeline antibiotics, it is evident that the health threats
posed by antibiotic resistance need to be tackled urgently, and in many different ways.
The last five years have seen important changes in practices, innovation and attitudes
in response to these growing threats. These are driving innovation in drug discovery and
diagnostics, but more importantly, in clinical practices and the ways in which antibiotics
are being used. There is also increasing local and international surveillance to monitor
the emergence and spread of antibiotic resistant strains, and local integrated practices,
antimicrobial stewardship programs and more effective diagnostic methods are being pushed
forward, in an effort to ensure the most appropriate and effective use of antibiotics.
These developments offer new opportunities for developers in this field, both in drug
discovery and in diagnostics.
Key Topics Covered:
For more information visit
Media Contact: Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets